Synlogic announces positive top-line phase 2 data for phenylketonuria (PKU); SYNB1934 advances to phase 3
Date：2022-10-18
Oct 18, 2022 — Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population
